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ABSTRACT
Protein tyrosine kinases (PTK) play essential roles in cell signal transduction
pathways. PTKs are associated with numerous diseases and promote oncogenic cell
signal transduction in unregulated forms. Thus PTKs represent a large group of
potential targets for anticancer drug discovery. Src was the first identified oncogene
and has been intensively studied for decades. The work described in this dissertation
studied the structure-function relationships of Src, to build a knowledge base for the
function of conserved residues in the kinase domain. To accomplish this, the first
focus of this dissertation was to develop a high throughput screening method to
identify kinase functionalities regarding catalytic activity and substrate specificity.
The

developed

method

utilizes

a

bacterial

screen

system

and

detects

phosphotyrosine in cell lysate by a high throughput manner. Combining the
developed functional screening with a rational mutation library, functional mutants
can be identified for further analysis. This in vivo strategy was validated by model
PTKs and could be universally applied to study kinase catalytic activity and substrate
specificity. A successful application of the developed method on the study of the
conserved HRD motif in Src led to a more comprehensive understanding of the role of
HRD in the kinase function.
The second focus of the dissertation was to study the regulatory function of the
arginine (R385) in the HRD motif of Src, since R385 was found unnecessary for
catalysis in the first part of this dissertation. The effect of R385 mutation on the key

regulatory mechanisms of Src and binding affinity towards PTK inhibitors was
examined. First, autophosphorylation of Tyr416 in Src activates this enzyme, and
overrides the negative regulation by Csk that phosphorylates Src on Tyr527. However,
mutation of R385 to other residues abolished this override. The presence of the
arginine prevents the transition of the active Src to inactivated Src. Second, type II
inhibitors bind to the inactive conformation of Abl but not to Src even through Src
and Abl are structurally very similar. Mutation of R385 greatly increased the affinity
of Src towards type II inhibitors, but had no effect on type I inhibitor binding, which
targets the active conformation. All together, when induced by Csk phosphorylation
or PTK inhibitors that target the inactive conformation of kinase domain, R385
behaves as an energy barrier in the conformational transition from active to inactive
conformation. The replacement of the R385 by any other amino acid made the
transition much easier. R385 is the first identified residue among protein tyrosine
kinases, that controls conformational transitions. This study sheds light on the
fundamental mechanism of regulatory conformational changes and provides more
insight on design and development of PTK inhibitors.
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CHAPTER 1
Introduction
1.1 Introduction to protein kinases
Upon the completion of the Human Genome Project[1], 518 putative protein
kinase genes have been identified, which is a strikingly large number and constitutes
about 1.7% of all human genes. This makes protein kinases one of the most
important enzyme families.

1.1.1 Signal transduction and protein kinases
Protein kinases mediate protein phosphorylation via transferring the
γ-phosphate of ATP to a target protein. Protein phosphorylation is a structural
modification, which often results in a conformational change of the target protein.
Conformational change of the protein further leads to functional and regulatory
change. As a post-translational modification, protein phosphorylation mediates signal
transduction and intracellular communication that controls diverse cellular
processes, including growth, development, division, replication, transcription,
differentiation, metabolism, apoptosis, homeostasis, motility and structural
rearrangements. It has been estimated that 30% of all cellular proteins are
phosphorylated on at least one site [2, 3].

1.1.2 Substrate specificity of protein kinases
1

All protein kinases phosphorylate target proteins on a select group of amino acid
side chains, including serine, threonine, or tyrosine, and thus protein kinases are
classified as protein serine/threonine kinases and protein tyrosine kinase. Among
identified protein kinases, each has one unique set of physiological substrates and the
number of substrates can be very different. For example, the Src family kinases have a
wide range of protein substrates while Csk family kinases display extremely narrow
range of substrates[4, 5].

Protein kinases phosphorylate their substrates selectively in order to maintain
the specificity and fidelity of diverse signaling pathways, which can be achieved by
different regulatory mechanisms. The local determinants around the active site can
direct the protein kinases to specific consensus phosphorylation sequences. The
distal docking parts of protein kinase and other adaptor protein or regulatory
proteins can also contribute to the high specificity[6].

2

1.2 Introduction to protein tyrosine kinases (PTKs)

Among human protein kinases identified, 90 have been identified as protein
tyrosine kinases. Despite the relatively large number of tyrosine kinases,
phosphorylation of tyrosine only accounts for less than 1% of total protein
phosphorylation. Besides, most tyrosine kinases are tightly regulated and only
activated under specific conditions. Unlike phosphorylation of serine or threonine
kinase, phosphorylated tyrosine rarely plays a structural role in proteins, and its role
primarily regulatory[2]. All these imply the importance of the tyrosine kinase.

1.2.1 Receptor tyrosine kinases and non-receptor tyrosine kinases
There are two main classes of protein tyrosine kinases: receptor tyrosine
kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Humans have 58 known
RTKs, falling into 20 subfamilies and 32 nRTKs falling into 10 subfamilies.

All RTKs possess an extracellular domain containing a ligand binding region, a
trans-membrane domain, and a cytoplasmic domain containing the kinase domain,
thus RTKs can directly receive extracellular signals. Growth factor binding activates
RTKs by inducing dimerization of receptor tyrosine kinases, including members of
the fibroblast, epidermal, vascular, endothelial, and insulin-like growth factors.
Ligand-induced dimerization leads to activation of the intracellular tyrosine kinase
domain by trans-phosphorylation, which is the fundamental regulatory mechanism
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mediating receptor tyrosine kinase activation. Activated RTKs will then proceed to
phosphorylate one or more downstream proteins and enzymes, initiating signaling
cascades.

Instead, nRTKs are referred to as cytosolic and do not exclusively associate with
the cell membrane. nRTKs receive signals through the association with intracellular
domains of other transmembrane receptors, including RTKs[7]. In addition, some
nRTKs have specific cytosolic function.

1.2.2 Src family kinases (SFK) and Src

The Src family kinases (SFKs) belong to nRTKs and are known as major
components to many growth factor signaling pathways. The SFKs include 8 members:
Blk, Fgr, Fyn, Hck, Lck, Lyn, Src, and Yes. Abnormally elevated SFK activity levels are
closely associated with oncogenesis in humans, particularly in certain types of colon
cancers, melanoma, leukemia, and lymphoma.

Src was the first identified oncogene and has been the subject of intense
investigation for decades [8]. Src has been implicated in playing significant roles in
both normal and pathological states. Src is found expressed ubiquitously and plays
key roles in cell morphology, motility, proliferation, and survival[9]. Src protein
tyrosine kinase activity is elevated in several types of human cancer, and this has

4

been attributed to both elevated Src expression and increased specific activity. In
breast cancer cells, members of the epidermal growth factor family are active and
may lead to activation of Src in the production of neoplasms. Src is also found
activated in colon, gastric, lung, pancreatic, neural, and ovarian neoplasms[10-12].
Thus, extensive work on the development of Src inhibitors has been performed.

Unlike BRAF or EGFR mutations or BCR-Abl fusion proteins, Src is not a primary
driver of tumorigenesis and Src mutants in tumors are very rare[11]. Most of the
time, Src participates in many pathways promoting cell division, invasion, migration
and survival and is downstream from the oncogenic drivers.

5

1.3 Structure of Src tyrosine kinase
1.3.1 Domain organization of Src tyrosine kinase
From amino-terminus to carboxyl-terminus, Src contains six distinct functional
domains: Src homologous domain 4 (SH4) with a 14-carbon myristoyl group attached,
unique domain, SH3 domain, SH2 domain, SH2-kinase linker, protein tyrosine kinase
domain (the SH1 domain), and a C-terminal regulatory segment.
In the SH4 domain, seven amino acids beginning with glycine are required for the
myristoylation of Src. Myristoylation facilitates the attachment of Src to membranes
and plays essential roles in SFK localization in the cytosol[13, 14]. Myristoylation,
subsequent membrane association and the Src protein kinase are involved in
transforming cells into a neoplastic state.
The unique domain is unique for each Src family member. The unique domain of
Src has been proposed to be important for mediating interaction with receptors or
proteins, which are specific for each family member[9].
The SH3 domain, around 60 amino acids, specializes in recognition of
proline-rich peptide sequences and adopts a left handed helical conformation,
consisting of five antiparallel β sheets and two prominent loops. SH3 contributes
greatly to localization and regulation of kinases or other SH3 domains [15].
The SH2 domain, around 100 amino acids, consists of a central three-stranded
β-sheet with a single helix packed against each other. The SH2 domain binds to
distinct phosphorylated tyrosine containing peptides and is responsible for
6

localization to RTKs and other enzymes that have been activated by tyrosine
phosphorylation.
Also, SH2 and SH3 have significant importance in Src function regulation. They
inactivate catalytic activity via intramolecular contacts and displacing the
intracellular SH2 or SH3 domains can activate Src activity. Proteins containing SH2
and SH3 can enhance their ability to function as substrates for Src protein tyrosine
kinases[16].

1.3.2 Architecture of Src catalytic domain
The Src catalytic domain consists of the featured bi-lobed protein kinase
architecture, a small amino-terminal lobe known as ATP-binding lobe and a large
carboxyl-terminal lobe known as peptide binding lobe. The N lobe is composed of a
five-stranded β sheet (β1-β5) and a prominent α helix, called helix αC. The C lobe
contains six conserved segments (αD-αI) and seven short β sheets (β6-β12). The
active site is located in the cleft between these two structural lobes[17]. ATP is bound
to the deep cleft and sits beneath a highly conserved loop connecting strands β1 and
β2, called the ATP-phosphate binding loop. Peptide substrates bind in an extended
conformation of active site with the assistance of a centrally located loop, known as
the activation loop. The activation loop typically has around 20~30 amino acids and
provides a platform for the peptide substrate. In most protein kinases, it begins with
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a conserved DFG motif and ends with a conserved APE motif. Moreover, the initial five
residues of the activation loop make up the magnesium-positioning loop. In most
kinases, there is an autophosphorylation site, which is responsible for activation of
kinase activity.

1.3.3 Catalytic signatures of Src
Protein kinases share highly conserved catalytic domains in the primary
sequence and these conserved individual amino acids are implied with significant
catalytic importance[17]. The chicken numbering system is used in this dissertation.
Among these conserved subdomains, a K/D/D motif is highly featured as the catalytic
core in the catalytic domain of Src. Lys295 in the K/D/D motif, forms ion pairs with
the α- and β- phosphates of the ATP and with Glu310 in the αC helix. Asp386, as the
catalytic base, occurs in the conserved motif HRD in the catalytic loop. It is thought to
orient the tyrosyl group of the substrate protein in a catalytically competent state. It
functions as a base that abstracts a proton from tyrosine thereby facilitating its
nucleophilic attacks of the γ-phosphorus atom of MgATP. Asp404 located in the
activation loop, is thought to bind Mg2+ or Mn2+ to coordinate the β- and γ-phosphate
groups of the ATP. Mg2+ is more likely the cation catalyst in the physiological state.

Comparison of residues exposed on the surface of active and inactive kinases
revealed a highly conserved spatial motif that was found in every active kinase but
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missing in inactive kinases. Local Spatial Pattern (LSP) alignment was developed to
compare and identify spatially conserved residues[18, 19]. This computational
analysis[18, 19] leads to the identification of hydrophobic structural skeletons of
catalytic domain, which suggests a catalytic spine with four hydrophobic residues and
a regulatory spine with eight hydrophobic residues.
Regulatory spine or R-spine consists of four inconsecutive residues, two from the
N-lobe: Leu325 from the β4 strand and Met314 from the αC helix; and two from the
C-lobe: Phe405 from DFG in the activation loop and His384 from HRD in the catalytic
loop. The backbone of H384 is anchored to the αF helix by a conserved aspartate
residue (Asp447), which serves as a base to the R-spine. The correct alignment of the
R-spine is essential for substrate positioning.
The catalytic spine or C-spine positions ATP and governs catalysis by facilitating
ATP binding. Two residues belongs to C-spine locate in the N lobe, Val281 in β2 and
Ala293 in the AXK motif of β3, directly docked onto the adenine ring of ATP. In the C
lobe, it is the Leu393, which is directly docked onto the adenine ring. Leu392 and
Leu394 flank the Leu393 and rest on a hydrophobic residue from the D-helix, Leu346.
Leu346 is in turn bound to the F-helix via Leu451 and Leu455.
The F helix is highly hydrophobic and functions as an organizing element for the
entire kinase core: C-spine anchors to the C terminus of the F helix ; R-spine anchors
to the N terminus of the F helix.

9

1.4 Regulation of Src tyrosine kinase
1.4.1 Phosphorylation and dephosphorylation of Src
Protein phosphorylation is a reversible and dynamic process that is mediated by
protein kinases and phosphoprotein phosphatases. Phosphorylation by a protein
kinase can stimulate or inhibit the activity of the substrate proteins, or provide
binding sites for the downstream effectors depending on the substrate and pathway.
Phosphoprotein phosphatases, which counteract the action of kinases, can reverse
the activity of substrate proteins or eliminate binding sites for downstream effectors.
Src and Src family protein kinases are tightly regulated by phosphorylation and
dephosphorylation and the dynamic effect of protein phosphatase and protein kinase
is crucial for substrate function[20-22].
One of the most important phosphorylation sites of Src is Tyr527, located on
the C terminal tail of Src (Figure 1. 1). Under basal conditions in vivo, 90-95% of Src
is phosphorylated at Tyr527[23]. Phosphorylation of Tyr527 inhibits Src catalytic
activity by engaging the SH2 domain in an intracellular interaction. This interaction
positions the SH3 domain and the connecting SH2 linker to the surface of the N lobe
of the catalytic domain, stabilizing the helix αC in an inactive conformation. The
C-terminal Src kinase (Csk)[24] and the Csk homology kinase (Chk)[25] catalyze the
phosphorylation of the inhibitory tyrosine of Src. Csk is expressed in all mammalian
cells, whereas Chk is limited to breast, hematopoietic cells, neurons and testes.
Whereas Chk inactivates Src by catalytic phosphorylation, Chk forms an inhibitory
10

non-covalent complex with Src[26].
Another major phosphorylation site of Src is Tyr416 (Figure 1. 1). It can undergo
autophosphorylation by another Src kinase molecule and then initiate a
rearrangement of the activation loop of the Src into its active configuration, which
stabilizes Src in its active conformation. When unphosphorylated, the activation loop
adopts a conformation blocking the binding of peptide substrate[27-29].
Furthermore, autophosphorylation on the activation loop overrides the inhibitory
regulation by the phosphorylation on Tyr527[30]. This regulation provides an
additional layer of control beyond the inactivation by Csk. Phosphorylated Tyr416
and rearranged activation loop together play a kinetic proofreading role. The
inhibition by Tyr527 phosphorylation is also found to be overridden by Tyr213
phosphorylation[31]. This kind of phenomenon has been well recognized in protein
phosphorylation reactions as a way of error correction. Many substrates need to be
phosphorylated at multiple sites before their function is altered, or primed by
phosphorylation before phosphorylation on the second site of the substrate.
In addition to the two major phosphorylation sites of Src discussed above, the
platelet-derived

growth

factor

receptor

(PDGF

receptor)

mediates

the

phosphorylation of Tyr 213 and actives Src activity. Tyr138 of Src can also be
phosphorylated by PDFG receptor in vitro, but the role of it is not clear yet. Src is also
phosphorylated by protein serine/threonine kinases.
Phosphorylated Tyr527 dephosphorylation by phosphatases is another
11

important mechanism for Src activation, including cytoplasmic PTP1B, Shp1 (Src
homology

2

domain-containing

tyrosine

phosphatase

1)

and

Sph2,

and

transmembrane enzymes including CD45, PTPα, PTPε, and PTPλ[11]. PTP-BL also
has been shown to dephosphorylate Src phosphotyrosine 416 in a regulatory manner.
It is suggested that the cellular expression of phosphotyrosine phosphatase has a role
on signal fidelity.
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Figure 1. 1

Adapted from: Xu, W., et al., Crystal structures of c-Src reveal features of its
autoinhibitory mechanism. Mol Cell, 1999. 3(5): p. 629-38
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Figure 1.1 A Model for Src Activation
(a) The inactive conformation of Src is stabilized by intramolecular interactions
among the kinase domain, the SH2/SH3 domains, and the phosphorylated C-terminal
tail. In this state, an inhibitory configuration of the activation loop helps disrupt the
kinase active site by stabilizing a displacement of the helix αC, which interferes with
substrate binding and protects Tyr416 from phosphorylation.
(b) Displacement of SH2 and/or SH3 domains, either by C-terminal tail
dephosphorylation or by competitive binding of optimal SH2/SH3 domain ligands,
allows the kinase domain to open, disrupting the inhibitory configuration of the
activation loop and exposing Tyr416 to phosphorylation.
(c) Phosphorylation of Tyr416 initiates a conformational reorganization of the whole
activation loop, relieving the steric barrier for substrate binding, allowing the helix
αC to move back into the active site, and reconstituting a fully active tyrosine kinase.
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1.4.2 Key elements regulating different conformations
Protein kinases can adopt different conformations through complicated
regulations. Two extreme conformations can be a fully active conformation and a full
inactive conformation[17, 32-35]. Structurally, the N lobe and C lobe can be oriented
differently, which results in an open or closed active site cleft. The two lobes can
move flexibly towards each other to open and close the cleft. The open form of the
cleft is necessary to allow the access of the ATP to the catalytic site and the release of
the ADP, and the closed form of the cleft is necessary to bring residues into the
catalytic domain.
Within each lobe, there is an essential segment that contributes the conformation
status of active site. In the N lobe, this segment is the major α-helix, known as the αC
helix. The αC helix rotates and orients with respect to the rest of the kinase domain,
stabilizing or destabilizing the active catalytic site. Glu310 in helix αC, as an absolute
conserved residue located, plays an important role in regulating the conformational
changes. In active conformation, the side chain of Glu310 forms a salt bridge with the
side chain of Lys295 that coordinates the α- and β- phosphates of ATP. In addition, the
helix αC makes direct contact with the N-terminal region of the activation loop,
linking the conserved DFG motif. The interaction between the DFG motif and the
Glu310-Lys295 salt bridge directly contribute to the conformation of helix αC to ATP
binding. In the inactive conformation of kinases, the Glu310-Lys295 salt bridge is
broken and Glu310 forms an alternative salt bridge with Arg385 or Arg409 in Src[29].
15

Different regulatory mechanisms often modulate kinase activity by altering the
integrity of these interactions, thereby altering the conformation of helix αC.
In the C lobe, the activation loop adjusts to make or break part of the catalytic site.
The activation loop has the capacity to undergo large conformational changes when
the kinases switch between inactive and active state[36]. Phosphorylation of the
activation loop stabilizes kinase in an open and extended conformation that is
permissive for substrate binding, which is featured in two aspects. First the Asp404
in the DFG motif at the amino-terminal base of the activation loop binds to the
magnesium ion. Second, the rest of the loop is positioned away from the catalytic
center in an extended conformation so that the C-terminal portion of the activation
loop provides a platform for protein substrate binding. In the inactive conformation
of Src[29], residues 413-418 of the activation loop form a short αhelix between the
small and large loop of the kinase domain, which buries the side chain of Tyr416.
Residues 404-411 of the activation loop push the αC helix out of its active state so
that Glu310 in the helix cannot form a critical salt bridge with Lys295.

16

1.5 Oncogene and therapeutic targets
Imatinib is the first developed small molecule compound used to treat Leukemia
caused by the Philadelphia chromosome, which is a specific genetic defect resulting
in an unregulated form of Abl. This unregulated Abl, known as BCR-ABL, alters the
signal transduction and leads to leukemia ultimately. BCR-ABL represents a typical
example of therapeutic targets and the success of imatinib guides continued
investigation and development of small molecule inhibitors[37].
Currently, 27 orally effective direct kinase inhibitors have been FDA-approved
targeting a limited number of enzymes[38]. Nearly all of the approved protein kinase
inhibitors are steady-competitive enzyme inhibitors with respect to ATP and they
interact with the ATP-binding pocket. Drugs can be tailored to bind specifically to
targets that exhibit differences. Structural studies have exploited differences within
the ATP-binding site and contiguous regions that can be used to provide specificity
for protein kinase inhibitors.

1.5.1 Classification of protein kinase inhibitors
Inhibitor classification can be complicated given diverse interactions between
inhibitor and protein tyrosine targets and the interaction of each inhibitor with a
protein kinase target is unique. Nevertheless, it is useful to classify these interactions
in order to apply them to the drug discovery process.
Small molecular protein kinase inhibitors have been characterized and classified
17

based on the binding property towards the target protein kinase [38-42]. Here we
use the classification Robert Roskoski Jr proposed based on the structures of
drug-enzyme complex determined by X-ray crystallography. These interactions are
classified by the activation state of target protein kinases that specifically include the
status of DFG-Asp and activation loop, the αC helix, and the regulatory spine.
Generally, most inhibitors are ATP competitive and fall into type I or type II inhibitors,
which are classified based on the states of the target enzyme. Type I protein kinase
inhibitors are characterized to bind with the active form of their protein kinase target
and type II inhibitors bind to the inactive conformation of the target protein kinase.
The specific states of the essential elements of the active site further subdivide the
type I inhibitors or type II inhibitors. Type III inhibitors are non-ATP competitive,
occupying a site next to the ATP binding pocket so that both ATP and the allosteric
inhibitor can bind to the target protein simultaneously. Type IV inhibitors bind
covalently to their protein kinase target.

1.5.2 Development of protein kinase inhibitors in the future
Regarding the significant importance of the protein kinase in both physiological
and pathological processes, we can foresee the demand on more targeted inhibitors
for numerous illnesses. The continued study of protein kinase structure and its
binding specificity towards current protein kinase inhibitors will serve as a basis for
the fundamental and applied biomedical breakthroughs.
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1.6 Objectives of this research
With the aim to study the structure-function relationship of PTKs regarding
catalytic activity and substrate specificity, the first project was to develop a rapid high
throughput screening method to select functional mutants of PTK. The second project
was focused on the functional study of Arg385 regarding the regulation of Src, which
was a functional mutant selected from the first project.

1.6.1 Development of a high throughput screening method to select functional
mutants
Site-directed mutagenesis is a method widely used as a common biochemical
approach to study structure-function relationship of PTKs. However, this strategy is
time consuming and less informative. Thus, the aim of the first project was to screen
catalytic activity and substrate specificity of PTKs in a high throughput manner with
no need to purify each mutant. The rapid screening method enabled the detection of
catalytic activity and the differentiation of substrate specificity among closely related
PTKs. A successful application of this strategy on the functional study of the HRD
motif of Src further validated the developed screening method. The strategy
described can be broadly applicable to other protein kinases of interest and freely
tailored based on distinct functional studies.

1.6.2 Functional study of R385 in the HRD motif regarding Src regulation
19

The first project led to a further study on the regulatory function of R385 and
thus the importance of R385 on conformational transition of the active site was
proposed and examined. The role of R385 on major Src regulations was explored and
then the affinity of several PTK inhibitors was determined for both the R385
mutation and wild type. These experiments revealed the importance of R385 in
controlling conformational changes and shed light on the selectivity of type II
inhibitors.
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2.1 Abstract
Protein Tyrosine Kinases (PTK) play important roles in both physiological and
pathological signaling pathways and have been studied extensively as potential drug
targets. Site-directed mutagenesis is one of the most traditional approaches for
structure-function analysis of PTKs. However, this approach requires the generation
and analysis of individual mutants and is time-consuming. In this study, a new
strategy was proposed to study kinase functionality using a high throughput
screening method. This new strategy utilizes a bacterial expression system to
co-express kinase mutants and substrates, and screens for catalytic activity and
substrate specificity by detecting phosphotyrosine in cell lysate in a high throughput
manner. Combining a rapid functional screening with a rational mutation library,
functional mutants can be identified for further analysis. This in vivo strategy has
been validated by model PTKs and can be universally applied to study kinase catalytic
activity and substrate specificity. A successful application of this strategy to study the
functionality of the HRD motif in Src demonstrated the power of this strategy and led
to further detailed understanding of the mechanism underlying the HRD motif.
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2.2 Introduction
As a post-translational modification, protein phosphorylation plays essential
roles in signal transduction and intracellular communication that control diverse
cellular processes [2, 3]. Protein kinases mediate protein phosphorylation via
transferring the γ-phosphate of ATP to the target proteins. Around 518 putative
protein kinase genes were identified with completion of the Human Genome Project,
and 90 of them have been identified as protein tyrosine kinases (PTK)[1]. Aberrant
tyrosine kinase activities play crucial roles in numerous diseases and malignant
transformation. Indeed, 51 out of the 90 tyrosine kinases are implicated in cancer
either through mutation or altered expression[43]. These associations greatly
encourage the development of inhibitors that would block the action of such protein
tyrosine kinases. The stunning success of imatinib in treating chronic myelogenous
leukemia (CML) further promotes that[44].
Src, as the first identified oncogene, has been the subject of intense investigation
for decades[45], and serves as a model in the study of other PTKs. A full
understanding of the oncogenic roles of protein tyrosine kinases on signal
transduction and rational drug design require the knowledge of the structural basis
of PTKs underlying the catalysis and substrate specificity. The catalytic domain of Src
is highly conserved among protein tyrosine kinases and the conservation of certain
amino acids suggests that they play functional or structural roles[46]. The Src
catalytic domain consists of the featured bi-lobed protein kinase architecture, a small
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amino-terminal lobe known as the ATP-binding lobe and a large carboxyl-terminal
lobe known as the peptide-binding lobe. The cleft of these two essential lopes is the
active site of Src[45]. The well-known catalytic loop is a highly conserved stretch of
amino acid residues located right in the catalytic cleft of the kinase domain. The HRD
motif located in the catalytic loop is considered as one of the most highly conserved
motifs and predicted to have significant functional importance[47]. Further
investigations are necessary for a full understanding of HRD motif function.
Researchers working on protein kinases widely use site-directed mutagenesis as a
conventional biochemical approach to study the structure-function relationships of
protein. However, the current site-directed mutagenesis studies experience great
difficulty. Routinely, site-directed mutants are generated, expressed, purified and then
characterized for functional analysis. This whole process is tedious and challenging,
while the result is not informative some of the time. Another part of the reason for
the complexity is that it requires a large number of mutants to fully evaluate the
structural feature required for the function of just a few residues. Thus we proposed a
new strategy to investigate the structural mechanisms of kinase activity and
substrate specificity.
In this study, we developed a rapid high throughput screening method to probe
the functionality of important conserved protein residues. To apply this developed
screening method to study the functionality of the HRD motif, each residue was
probed by catalytic activity screening of a saturated mutagenesis library. Functional
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mutants from the screening were selected for further study. Screening analyses of
H384 and D386 are consistent with previous findings and support the model of
functionality proposed previously. Interestingly, we found that a wide range of
structurally diverse amino acids were able to replace the HRD arginine and maintain
approaching full catalytic activity. This discovery may indicate significant importance
of R385 on regulation of kinase activity, which requires further analysis.
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2.3 Results
In this study, a rapid screening method to probe kinase activity and substrate
specificity in a high throughput manner was developed to overcome the drawbacks of
traditional site-directed mutagenesis method. The proposed screening strategy using
the developed method to identify functional mutants is shown in Figure 2.1. A library
harboring random mutations in a kinase of interest will be introduced into a bacterial
screening system. The colonies expressing an active kinase were be selected through
colony blot using an antibody against the specific phosphotyrosine. Functional
mutants were investigated for further functional analysis. Unlike site-directed
mutagenesis, this strategy provides functional mutants for further analysis.
2.3.1 Bacterial proteins are phosphorylated on tyrosine residues when PTKs
are heterogeneously expressed in E coli.
To demonstrate E. coli as a good screening system for catalytic activity, four
representative protein tyrosine kinases were chosen, Abl, Csk, FGFR, and Lck. Each
kinase was cloned into pGEX-4T-1 in DH5α and expressed at 370C for 24 hours. The
level of tyrosine phosphorylated bacterial proteins was detected by a monoclonal
antibody specific for general tyrosine phosphorylation, using an empty vector
without a kinase as a control. As shown in Figure 2.2, a large range of bacterial
proteins with different molecular weights got phosphorylated on tyrosine. This
demonstrates that PTKs, when expressed in E. coli, are able to phosphorylate
bacterial proteins on tyrosine to a higher level than the bacteria’s own
37

phosphorylation level.
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Figure 2.1

A) A library harboring random
mutants will be created with
rational design

B) The library will be
introduced into a bacterial
screening system developed
for
specific
functional
selection

C) Functional mutants will be
selected
through
the
developed screening method

D) Further functional analysis of selected mutants
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Figure 2.1 Scheme of the screening strategy
The screening strategy couples a bacterial based screening with a random mutation
library of interest. A) A library harboring random mutants is created with rational
design. B) The library is introduced into a screening system developed for specific
functional selection. C) Functional mutants are picked through the developed
screening method. D) Further functional analysis of selected mutants
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Figure 2.2
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Figure 2.2 General tyrosine phosphorylation on bacterial proteins by
representative PTKs when expressed in E. coli
As described in the Materials and Method section, samples were collected from
overnight cultures and analyzed with a monoclonal antibody specific for general
tyrosine phosphorylation. The same amount of soluble cell lysate for each PTK
sample was compared with that when just empty vector expressed in DH5α: Lane 1,
empty pGEX-4T-1 vector; line 2, Abl; line 3, Csk; line 4, FGFR; line 5, Lck.
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2.3.2 Substrate specificity can be screened when a protein tyrosine kinase and
a specific substrate are co-expressed in the E. coli expression system
Substrate specificity of protein kinases is essential for the fidelity of signal
transduction. Thus we further developed and optimized this bacterial screen system
to analyze substrate specificity of PTKs. To achieve this, a specific substrate should be
co-expressed with kinases. After rounds of development and optimization, it was
determined that specific substrate could be expressed using a high copy number
plasmid while kinase could be expressed using a low copy number. This setup was
chosen with the idea that in a typical kinase reaction, there should be a much higher
concentration of the substrate than that of the kinase.
To validate the proposed expression strategy for substrate specificity screening,
Abl, Csk and Src were used as models of PTKs with very different substrate specificity.
Abl recognizes Crk-L as a physiological substrate and phosphorylates it on Tyr207
specifically[48]. KdSrc served as substrate for both Csk and Src: Csk phosphorylates
KdSrc on Tyr527; Src phosphorylates KdSrc on both Tyr416 and Tyr527[49].
To screen substrate specificity towards Tyr207 on Crk-L, the PTKs, Abl, Csk and
Src each encoded in pCDF-1B, a low copy number plasmid, were co-expressed
respectively with Crk-L encoded in pRSET-A, a high copy number plasmid. The
phosphorylation levels on Tyr207 of Abl, Csk, and Src were compared with empty
pCDF-1B vector expressed using a monoclonal antibody specific for pY207 in Crk-L.
To screen substrate specificity towards Tyr416 on Src, Abl, Csk and Src encoded in
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pCDF-1B, using empty pCDF-1B as a control, were co-expressed respectively with
KdSrc encoded in pRSET-A. The phosphorylation levels of Tyr416 were determined
by western blot using a monoclonal antibody specific for pY416 on Src. To screen
substrate specificity towards Tyr527 of Src, Abl, Csk and Src were co-expressed
respectively with KdSrc as above and the phosphorylation levels of Tyr527 were
determined by western blot using a monoclonal antibody specific for pY527 of Src. As
shown in Figure 2.3, Abl phosphorylated Crk-L significantly more than Csk and Src;
Src phosphorylated KdSrc on Tyr416 significantly more than Abl and Src; Src and Csk
phosphorylated KdSrc on Tyr527 significantly more than Abl. These results
demonstrate that when specific substrate is co-expressed with specific PTKs,
substrate specificity can be differentiated among PTKs.
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Figure 2.3
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Figure 2.3 Substrate specificity screening of model PTKs in developed method
Model PTKs, Abl, Csk, and Src were cloned into pCDF-1B plasmid respectively and
substrates Crk-L and KdSrc were cloned into pRSET-A plasmid respectively. (A)
Substrate Crk-L was co-expressed with PTKs and the phosphorylation levels of Y207
on Crk-L were compared between PTKs and empty vector pCDF-1B. (B) Substrate
KdSrc was co-expressed with PTKs and the phosphorylation levels of Y416 on KdSrc
were compared between PTKs and empty vector pCDF-1B. (C) Substrate KdSrc was
co-expressed with PTKs and the phosphorylation levels of Y527 on KdSrc were
compared between PTKs and empty vector pCDF-1B.
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2.3.3 Adaption of the proposed strategy to study the HRD motif in Src
Protein kinases share conserved features with functional importance[17]. HRD is
a highly conserved motif in the active site and predicted with important function. In
this study, the proposed screening strategy was applied to study the catalytic function
of HRD motif in Src. Each residue of the HRD motif was random mutated to create a
mutation library as described in the method section. Each mutation library was
screened thoroughly for catalytic activity and functional mutants were selected for
structure-function analysis.
It has been demonstrated that fully active Src is toxic to the bacterial host and
can’t be expressed and purified in bacteria. Co-expression with a protein tyrosine
phosphatase (PTP) can reduce the toxicity to allow the fully active Src to be expressed.
However, the co-expressed phosphatase may remove the phosphorylation of bacterial
proteins to an undetected level for low activity kinase. Low activity Src mutants can
be expressed without the phosphatase[50]. Thus we decided to use a PTP system and
a non-PTP system for screening of Src kinase mutants: the PTP system expressed Src
mutants with PTP1B and GroESL in BL21(DE3)RIL as described [51]; the non-PTP
system expressed Src mutants with GroESL in BL21(DE3)RIL. The combination of the
two expression systems would be suitable for screening both high activity and low
activity mutants. There wasn’t a positive control for the non-PTP system since wild
type Src was toxic for bacterial growth without co-expression of a phosphatase. Thus,
in the non-PTP system, any mutant that showed a higher signal than the negative
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control was selected as a functional mutant for further analysis. Additionally, two Src
mutants were generated to validate the screening system for catalytic activity of Src,
KdSrc and SDSrc. KdSrc was a kinase-defective mutant of Src (kdSrc), which was
different from active Src with a point mutation (Lys295Met) and SDSrc was a
truncated mutant at R385 position, which had only half of the catalytic domain of Src.
Neither KdSrc nor SDSrc should have any phosphorylation of bacterial proteins other
than bacteria’s own phosphorylation.
WtSrc, KdSrc and SDSrc were expressed in PTP system for 24h at 370C. Soluble
fractions from cell culture were analyzed by western blot using a monoclonal
antibody specific for general tyrosine phosphorylation. Src is known to
autophosphorylate on Tyr416 in the activation loop and thus the phosphorylation
levels of Tyr416 was also explored in the soluble fractions[45]. WtSrc was shown to
phosphorylate the bacterial proteins and the Tyr416, whereas neither KdSrc nor
SDSrc were detected with any phosphorylation (Figure 2.4). In the Tyr416
phosphorylation blot, comparison between WtSrc and KdSrc indicated that substrate
specificity towards Tyr416 of Src was also retained in the screening, in which Src
served as a specific substrate for itself (Tyr416 was lost in the truncated form of Src,
SDSrc). In the general phosphorylation blot, WTSrc phosphorylated a wide range of
bacterial

proteins

compared

with

KdSrc

and

SDSrc,

in

addition

to

autophosphorylation. All together, the results demonstrate that in the PTP system,
general tyrosine phosphorylation blot screens general catalytic activity of Src and
48

phosphorylated Tyr416 blot screens substrate specificity activity of Src.
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Figure 2.4
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Figure 2.4 Validation of developed catalytic screening method for HRD motif in
PTP system
WtSrc and Src mutants were co-expressed with GroESL and PTP1B in PTP system.
WtSrc (wild type), KdSrc (a kinase defective form of Src (Lys295Met)) and SDSrc (a
truncated form of Src (truncated at Arg385 position)) were expressed at 370C for 24
hours. The same amounts of soluble fractions were analyzed by western blot with
monoclonal antibodies specific for general tyrosine phosphorylation and Tyr416
phosphorylation, respectively.

51

2.3.4 Screening study of H384 residue on catalysis
An H384 mutation library was created and screened for general catalytic activity
as described in the method section. Representative screening results from PTP
system and non-PTP system, respectively, are shown in Figure 2.5. From the
screening in PTP system, there was only one or none functional mutant selected on
average for each 96-well screening (Figure 2.5A). With ~650 random mutants
screened, 5 mutants were selected as functional mutants all together. All five mutants
had histidine on H384 position and had different genetic codons, which indicated
that only wild type was selected for this position from the created mutation library. In
non-PTP system, ~20-40 mutants on average had significant phosphorylation signal
compared with KdSrc and SDSrc for each 96-well screening (Figure 2.5B). Fifty
random functional mutants were selected and sequenced, and led to the
identification of nine different mutations, including H384Q, H384Y, H384T, H384S,
H384F, H384L, H384V, H385I and H384G. Wild type Src was not selected from the
screening in non-PTP system because the lack of phosphatase.
The phosphorylation signal produced in screening may not be quantitative due
to many factors including culture density, growth phase, expression level of kinase,
sensitivity of antibody and other unknown factors. Based the screening results from
the two screening systems described, the catalytic activity of H385 mutants would
have relatively low activity because the mutants were selected only within non-PTP
system. In the PTP system, the co-expressed phosphatase might remove the
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phosphorylation of the bacterial proteins to an undetected level because of the low
kinase activity.
To confirm the catalytic activity of H384 mutants, all of the mutants selected
from the screening were expressed and purified. The relative Src activity of H384
mutants was determined using polyE4Y as substrate (Figure 2.6). All mutants
maintained active kinase activity and H385Q had the highest catalytic activity among
H385 mutants, ~14% of wild type activity. Among the selected mutants, H384F
(10.2%), H384L (1.1%), H384V (0.6%) H385I (0.6%) and H384G (0.2%), are
hydrophobic amino acids that can maintain marginal catalytic activity, supporting the
proposed

hydrophobic

interaction

of

His384

in

stabilizing

the

active

conformation[18]. H384Q (14.2%), H384Y (6.2%), H384T (6.0%) and H384S (2.6%)
are polar amino acid replacements, which may still maintain the hydrophobic
interaction and hydrogen bond formation as histidine. The contribution of the
polarity of the side chain is not clear and needs further study of it[47].
Some of the H384 mutants have been characterized previously. The histidine
mutation to leucine in Src64 reduces the kinase activity to 27% of the wild type and
produces significant defects in its biological function on development[52]. The
histidine mutations to glutamine, tyrosine and alanine in Src also reduce the kinase
activity[50]. The replacements of the corresponding histidine to tyrosine,
phenyalanine and arginine in Aurora A impair the kinase activity and the ability of
autophosphorylation is only maintained in the histidine to tyrosine mutant[53]. The
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crystal structure of the histidine to arginine mutant of Aurora A displays a disruption
in the hydrophobic structural skeletons of the catalytic core. In stead, the histidine to
tyrosine mutant displays a changed geometry of it. The results of H384 screening are
consistent with previous research.
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Figure 2.5
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Figure 2.5 Representative catalytic activity screening results of an H384
mutation library
An H384 mutation library was constructed as described in Method section. Controls
and H384 library mutants were inoculated into a 96-well plate and blotted by a
monoclonal antibody specific for general tyrosine phosphorylation. Each control was
inoculated repeatedly in two wells and each mutant was inoculated once into one
well. The cell lysate from each well was blotted twice in the nitrocellulose membrane.
The blot results were labeled in a 96-well manner. (A) A representative screening blot
of H384 library in PTP system: A1, A2, D1 and D2 had WtSrc expressed as positive
controls; B1, B2, E1 and E2 had KdSrc expressed as negative controls; C1, C2, F1 and
F2 had SDSrc expressed as negative controls. The rest of the wells had random H384
mutants expressed for screening selection. (B) A representative screening blot of
H384 library in non-PTP system: A1 and A2, had WtSrc expressed in PTP system as
positive controls; B1 and B2 had KdSrc expressed as negative controls; C1 and C2 had
SDSrc expressed as negative controls. The rest of the wells had random H384
mutants expressed for screening selection.
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Figure 2.6 Relative catalytic activity of Src H384 mutants
The catalytic activity of selected H384 mutants toward an artificial substrate, polyE4Y
was determined. WtSrc at 3nM concentration were incubated with 200uM ATP,
12mM MgCl2 and 1mg/ml polyE4Y in the kinase assay buffer for 30min. Catalytic
activity of H384 mutants were determined at 30nM or higher dependent on the
activity of the mutant. The relative Src catalytic activity was determined by ADP
production as described in the method section.
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2.3.5 Screening study of R385 on catalysis
An R385 library was created and screened for general catalytic activity, and
representative screening results for PTP system and non-PTP system respectively are
shown in Figure 2.7. In both expression systems, a large number of mutants had
significant phosphorylation signals compared with negative controls (Figure 2.7A
and 2.7B). From each screening system, ~50 functional mutants were selected and
sequenced. There was an overlap on the selection of replacement amino acids
between the PTP system and non-PTP system, while other mutations only showed up
in either one. R385Q and R385Y were mutants selected only from non-PTP system,
while R385K, R385V, R385N, R385L, R385C and WtSrc were only found in the PTP
system. R385A, R385G, R385S, and R385T were selected from both systems. These
results indicated that a variety of R385 mutants maintained significant catalytic
activity.
Selected mutants from the PTP system were purified and the catalytic activity was
determined by the kinase assay using polyE4Y as substrate (Figure 2.8). As shown,
mutants selected from the PTP system including R385N (88.3% of wild type Src
activity), R385V (85.4%), R385C (70.0%) and R385K (43.6%), R385L (35.9%),
R385T (30.8%), R385A (27.9%), R385G (19.3%) and R385S (17.2%), had catalytic
activity ranging from ~17.2 to 100% of wild type Src kinase activity. This result
indicated that selected R385 mutants maintained significant catalytic activity in the
standard kinase assay and the selective range of the PTP system was at least ~17% of
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the wild type Src activity or above. While R385 mutants selected from both systems
included R385A (27.9%), R385G (19.3%), R385S (17.2%), and R385T (30.8%),
which indicated that the selective range for non-PTP system was at most ~31% of the
wild type activity or below. This was also consistent with the finding that no His384
mutants but WtSrc was selected from the PTP system and the most active H385Q
screened from non-PTP system had 14.2% of the wild type Src activity. Based on the
observation that the H384 mutants selected only from non-PTP system had catalytic
activity ranging from ~0.5 to 14.2%, the selection range for non-PTP system should
be ~0.5 to 30.8% of the wild type Src kinase activity.
The results of R385 screening are consistent with the previous report that
mutation of the HRD arginine to cysteine on Src64 has very little effect on kinase
activity[52]. Besides, the R385 is not as universally conserved as D386 in all
kinases[46]. All together, based on the results from the R385 random mutation
screening and the standard kinase assay on selected R385 mutants, it is clearly
shown that R385 is not essential for catalysis.
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Figure 2.7
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Figure 2.7 Representative catalytic activity screening results of an R385
mutation library
An R385 mutation library was constructed as described in the Methods section.
Controls and R385 library mutants were inoculated into a 96-well plate and blotted
by a monoclonal antibody specific for general tyrosine phosphorylation. Each control
was inoculated repeatedly in two wells and each mutant was inoculated once into one
well. The cell lysate from each well was blotted twice in the nitrocellulose membrane.
The blot results were labeled in a 96-well manner. (A) A representative screening blot
of the R385 library in the PTP system: A1 and A2 had WtSrc expressed as positive
controls; B1 and B2 had KdSrc expressed as negative controls; C1 and C2 had SDSrc
expressed as negative controls. The rest of the wells had random R385 mutants
expressed for screening selection. (B) A representative screening blot of R385 library
in the non-PTP system: A1 and A2 had WtSrc expressed in the PTP system as positive
controls; B1 and B2 had KdSrc expressed as negative controls; C1 and C2 had SDSrc
expressed as negative controls. The rest of the wells had random R385 mutants
expressed for screening selection.
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Figure 2.8 Relative catalytic activity of Src R385 mutants
The kinase activity of selected R385 mutants toward an artificial substrate, polyE4Y
was determined. WtSrc and R385 mutants at 3nM kinase concentration were
incubated with 200uM ATP, 12mM MgCl2 and 1mg/ml polyE4Y in the kinase assay
buffer for 30min and the relative Src catalytic activity was determined by ADP
production as described in the method section.
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2.3.6 Screening study of D386 residue on catalysis
A D386 library was created and screened for general catalytic activity, and
representative screening results for the PTP system and non-PTP system are shown
in Figure 2.9. Totally 630 random mutations were screened for each screen system
and none was selected except for WtSrc from the PTP system. This result indicated
that replacement by any other residue for Asp386 couldn't retain even 0.5% kinase
activity based on the previous assessment of the screen method. This result supports
Asp386’s indispensable role in catalysis and is consistent with previous studies of the
functionality of Asp386[29]. Asp386, as a signature of the catalytic core, is thought to
orient the tyrosyl group of the substrate protein in a catalytically competent state. It
functions as a base that abstracts a proton from tyrosine thereby facilitating its
nucleophilic attacks of the γ-phosphorus atom of MgATP[29]. Mutation of the
corresponding Asp386 abolishes the catalytic activity in many protein kinases[54,
55].
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Figure 2.9
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Figure 2.9 Representative catalytic activity screening results of A D386
mutation library
A D386 mutation library was constructed as described in Method section. Controls
and D386 library mutants were inoculated into a 96-well plate and blotted by a
monoclonal antibody specific for general tyrosine phosphorylation. Each control was
inoculated repeatedly in two wells and each mutant was inoculated once into one
well. The cell lysate from each well was blotted twice in the nitrocellulose membrane.
The blot results were labeled in a 96-well manner. (A) A representative screening blot
of D386 library in PTP system: A1, A2, D1 and D2 had WtSrc expressed as positive
controls; B1, B2, E1 and E2 had KdSrc expressed as negative controls; C1, C2, F1 and
F2 had SDSrc expressed as negative controls. The rest of wells had random D386
mutants expressed for screening selection. (B) A representative screening blot of
D386 library in non-PTP system: A1, A2, D1 and D2 had WtSrc expressed in PTP
system as positive controls; B1, B2, E1 and E2 had KdSrc expressed as negative
controls; C1, C2, F1 and F2 had SDSrc expressed as negative controls. The rest of the
wells had random D386 mutants expressed for screening selection.
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2.4 Discussion
We have witnessed a bloom in the field of directed protein engineering in the last
decade. However, this approach requires high throughput screening or selection[56].
Even though this approach has been widely applied to study different enzyme
families[57-60], it has not been applied to PTKs due to the lack of high throughput
screening method for functional mutant selection.
Here we developed a bacterial based high throughput screening method, to
identify kinase functionalities. First, when PTKs are heterologously expressed in E.
coli, the catalytic activity is screened by the detection of phosphorylated bacterial
proteins in the cell lysate. Second, when PTKs and specific substrates are
co-expressed in bacterial system, the substrate specificity is screened by the
detection of specific phosphorylated substrates in cell lysate. This developed
screening method was successfully adapted to study the HRD motif of Src, which
resulted in a more clear understanding of the role of this motif in the kinase function.
The great advantage of this proposed screening strategy is that any mutant selected
from the screening is functional and informative. Thus this strategy overcomes the
blindness in the traditional random mutagenesis strategy and provides a more
comprehensive analysis. The developed screening method on Src catalytic activity can
be directly applied to the functional study of other conserved residues or motifs of
interest in Src based on the successful application of the study on the HRD motif. Also,
this proposed versatile strategy could be adapted for diverse functional studies
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regarding catalytic activity and substrate specificity of PTKs. To achieve this, the
kinase or substrate of interest can be readily introduced into the developed screening
method and functional mutants can be screened with rational design.
Characterization of HRD motif of Src with this proposed strategy led to a more
comprehensive understanding of the functionality of it. First, a large group of amino
acids with hydrophobic property can replace the histidine and maintain a significant
fraction of the catalytic activity of Src. This finding is consistent with previous
functional studies of the corresponding H384 on protein kinase and supports the
proposed role of H384 as one of identified surface conserved residue forming
hydrophobic structural skeletons of catalytic domain[18, 61]. Second, a wide range of
structurally diverse amino acids can replace the R385 residue and maintain
approaching full catalytic activity of Src. This result suggests that R385 is not
essential at all in catalysis or maintaining active conformation. Finally, the D386
residue can’t be replaced at all and this supports its essential role as a catalysis base.
This study of the HRD motif of Src using the developed screening method also
raises an important question that remains to be answered. The HRD arginine seems
unnecessary in this catalysis, but it is still chosen by evolution for a large group of
protein kinases. The conservation suggests this arginine must give Src and other
PTKs certain biochemical property that confers a selective advantage in evolution.
The unique function of this arginine, for the group of protein kinases that choose
arginine, still needs to be solved. The protein kinases, which take other amino acids
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instead of arginine, may have a different regulatory mechanism underlying this
position. These substantial discoveries in this study demonstrate the power of the
developed high throughput screening method. This proposed screening strategy
would be of great help for the selection of PTK mutants with altered properties and
lead to recognition of residues important for catalysis and substrate specificity.
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2.5 Materials and methods
2.5.1 Reagents and chemicals
Consumables and culture media, or media components, were purchased from
Fisher Scientific. Specific antibodies were purchased from Cell Signaling Technology.
All the other chemicals were purchased from Sigma.
2.5.2 Molecular cloning and protein expression
Abl, Csk, FGFR, and Lck were cloned into pGEX-4T-1 plasmid and transformed
into DH5α for catalytic activity screening. Src and Src mutants were cloned into the
pRSETA plasmid and transformed into E.coli BL21(DE3)RIL. Substrate KdSrc and
Crk-L were cloned into pRSETA plasmid and PTK Abl, Csk and Src were cloned into
pCDF-1B plasmid. Substrate and each PTK were co-expressed in E.coli BL21(DE3)RIL.
Src mutants including KdSrc, and SDSrc were generated by site-directed
mutagenesis(Stratagene). All constructs were verified by sequence analysis. Plasmids
were introduced into the specific expression systems by electroporation.
2.5.3 Mutation Library Construction and Screening
Random mutant libraries of each residue were generated by site-directed
mutagenesis using primers containing random sequences at position H384, R385 and
D386, respectively. The SDSrc clone was used as the template in site-directed
mutagenesis to avoid wild type Src plasmid contamination in constructed libraries.
Each library was expressed in E.coli BL21(DE3)RIL. The mutant library was
introduced into the expression systems by electroporation and each transformant
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from a mutation library was inoculated into a well of 96-well plate containing 200ul
LB broth with appropriate antibiotics. The plate was incubated for 24h in a 370C
shaker. Then 0.4ul of the cell culture was blotted twice directly onto a nitrocellulose
membrane and followed by western blot using anti-phosphotyrosine mouse
monoclonal antibody (PY100; Cell Signaling Technology) and horseradish peroxidase
(HRP)-anti-mouse secondary antibody (Stratagene).
2.5.4 Expression and purification of Src and mutants
Src and Src mutants were constructed in the pRSETA expression plasmid. The
Src constructs were expressed in E.coli BL21(DE3)RIL cells harboring the
pREP4groESL plasmid expressing the GroES/EL chaperone and the pCDF-PTP1B
plasmid expressing protein tyrosine phosphatase PTP1B. The (His)6-tagged Src
constructs were purified using immobilized Ni-iminodiacetic acid-agarose as
described previously[62]. Concentration and purity of each enzyme were determined
by Bradford assay and SDS-PAGE, respectively. Purified enzymes were stored in 50%
glycerol at -200C.
2.5.5 Kinase assay
Kinase activity of Src and mutants was determined using polyE4Y and ATP as the
substrates. The phosphorylation reactions were performed in 50ul volumes at 25oC
in

the

protein

kinase

assay

buffer:

50

mM

N-(2-hydroxyethyl)piperazine-N′-3-propanesulfonic acid (pH 8.0) containing 5%
glycerol, 0.005% Triton X-100, and 0.05% 2-mercaptoethanol. The standard assay
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used 12 mM MgCl2, 0.2 mM ATP, and 1 mg ml–1 polyE4Y. After a 30 min reaction time,
5ul of the kinase reaction mixture was mixed with 5ul of ADP-GloTM reagent and
incubated for 40 min to stop the kinase reaction and deplete the unconsumed ATP.
10ul of Kinase Detection reagent was added and incubated for another 30 min to
convert produced ADP to ATP and introduce luciferase and luciferin to detect
converted ATP. Then the luminescence produced was measured by a plate-reading
luminometer. Assays were performed in duplicate, and each assay was repeated three
times with reproducible results.
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3.1 Abstract
Protein Tyrosine Kinases (PTK) play important roles in both physiological and
pathological signaling pathways and have been studied extensively as potential drug
targets. Conformational changes of PTKs tightly regulate their biological function and
impact the affinity towards PTK inhibitors. In this study, the R385 residue on the
model PTK, Src, was revealed to play a crucial role in the conformational changes that
underlines Src regulation and inhibitor binding. First, R385 mutation to a number of
unrelated residues can maintain catalytic activity approaching that of wild type.
Second, R385 is not necessary for the activation of Src through autophosphorylation
on Tyr416 in the activation loop. Third, autophosphorylated R385 mutants can still
be down regulated by Csk, while autophosphorylation prevents Csk inactivation of
wild type Src. Fourth, R385 mutation displays strikingly increased affinity toward
type II protein kinase inhibitors compared to the wild type, which target the inactive
conformation of the active site. In contrast, R385 mutants maintain similar affinity
towards type I inhibitors as wild type, which target the active conformation.
Altogether, these experimental results demonstrate that the R385 residue is critical
for Src transitions from an active to an inactive conformation. The study of R385
defines a new functional cluster, which regulates the transition between
conformational states. This study sheds light on the fundamental mechanism of
regulatory conformational changes and provides more insight on design and
development of PTK inhibitors.
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3.2 Introduction
The human genome contains 518 protein kinase genes which constitute about
1.7% of all human genes [1]. They mediate essential signal transduction pathways
in both normal and pathological states [1-3, 6, 20], which makes them useful targets
for drug design and development[11, 37-39, 63]. Thus the understanding of the
regulatory mechanisms of protein kinases has significant relevance.
Src is the first identified oncogene and expressed ubiquitously, which has been
the subject of intense investigation for decades [9, 11, 12, 16]. Src has multi-layered
and integrated regulatory mechanisms, including activation by autophosphorylation
and inactivation by tail phosphorylation. Autophosphorylation on the activation loop
is a common strategy to activate most protein tyrosine kinases. Upon
autophosphorylation on Tyr416 in Src, the activation loop is rearranged and the
active site is stabilized in an active conformation[45]. Src is also inactivated by
phosphorylation of Tyr527 residue on the C terminal tail by Csk. The phosphorylated
Tyr527 engages the SH2 domain in an intramolecular interaction that stabilizes the
inactive conformation.

Similar to all protein kinases, the Src kinase domain has bi-lobed architecture: a
small amino-terminal lobe known as the ATP-binding lobe and a large
carboxyl-terminal lobe known as the peptide binding lobe. The active site is located
in the cleft between these two structural lobes[17]. The catalytic loop, located in the
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active site, starts with a highly conserved HRD motif, but the role of these conserved
residues are not fully defined[18, 29, 33, 52, 64]. In the crystal structure of the
autophosphorylated Src family kinase, Lck, the HRD arginine binds to the
autophosphorylated Tyr416. It was proposed that this interaction helps stabilize the
active conformation of the Src kinase domain. This proposal, however, has not been
directly tested. The Arg residue has also been proposed to stabilize the inactive
conformation of Src by forming a salt-bridge with conserved Glu310 from the N-lobe.
Furthermore, whether the Arg residue plays any other catalytic or regulatory roles
has not been studied. A comprehensive examination of the potential roles for these
highly conserved residues would be necessary for understanding its contribution to
the function of the kinase. Because Src is a well-recognized model of other protein
tyrosine kinases, such an understanding may shed light on the structure-function
understanding of other kinases.
Another important goal of structure-function studies of Src is to provide a
rationale for drug design. Currently most PTK inhibitors bind to the active site as
ATP-competitive inhibitors. How the conserved features in the active site of a kinase
contribute to the binding affinity and specificity of inhibitors is also a critical
question to answer. More specifically, for example, how the HRD motif contributes to
the binding toward various inhibitors has not been examined. A comprehensive
examination could provide a basis for understanding inhibitor binding and selection.
In the previous chapter, we demonstrated that Arg385 can be replaced by a
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large number of structurally unrelated residues without compromising the kinase
activity of Src, indicating that the Arg residue does not play a catalytic role. In this
study, we demonstrate that this Arg residue controls the transition from active to
inactive conformations that underlies the Src regulation by Csk and inhibition by
certain small molecular inhibitors.
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3.3 Results
3.3.1 Substitution of Arg385 by a wide range of amino acids still retains the
catalytic activity of Src
Src has the conserved HRD motif in its catalytic loop. The understanding of Src
R385 in the HRD motif is still limited to crystallographic studies that reveal its
interactions. To fully understand the functionality of Arg385 of Src, a mutant library
containing random replacements on Arg385 as described in the previous chapter was
screened for the catalytic activity of Src. A wide range of amino acids was selected
from the catalytic screening, which substituted arginine at the 385 position and
maintained significant Src catalytic activity (Figure 2.7). All of the R385 mutants
maintained significant catalytic activity in the standard kinase assay using polyE4Y as
a substrate (Figure 2.8). A few of the R385 mutants had almost the same catalytic
activity as the wild type, including R385N (88.3% of wild type Src activity), R385V
(85.4%), R385C (70.0%) and R385K (43.6%). Surprisingly, some of the substitutions
didn’t share any obvious similarities with Arg. This result indicates that R385 is not
essential for catalysis and amino acids with very diverse functional side chains can
maintain approaching full kinase activity of wild type.
To further study the functionality of the R385 residue, R385V as a hydrophobic
side chain substitution, R385K as a positive charged side chain substitution, R385N
as a polar side chain substitution with an amino group, and R385C as a polar side
chain substitution with a sulfhydryl group were used as representative mutants for
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further functional study of R385.
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3.3.2 R385 mutation retained Src activation regulation associated with
autophosphorylation
Previous research suggests that R385 is a highly conserved and structurally
important residue. In the crystal structure of an active conformation of Src family
kinase, Lck, the corresponding Arg on HRD motif is coordinating the phosphorylated
tyrosine on the activation loop along with another Arg on the activation loop,
R409[33]. Based on this observation, it is reasoned that the Arg385 is stabilizing the
active conformation of Src when Src is autophosphorylated on Tyr416. Thus the
effect of R385 mutation on Src activation associated with autophosphorylation was
examined.
The autophosphorylation of WtSrc and R385 mutants was first examined to see if
R385

mutants

could

still

autophosphorylate

on

the

activation

loop.

Autophosphorylation can be achieved by incubating the enzyme with ATP and Mg2+ in
the kinase assay buffer. WtSrc and R385 mutants at the same concentration of 450nM
were incubated and fractions were removed at indicated period of time for western
blot detecting the level of phosphorylated Tyr416 (Figure 3.1). Results showed that
WtSrc and R385 mutants reached saturated phosphorylation after 30 min incubation.
It was difficult to determine the rate difference between WtSrc and R385 mutants
because when enzymes were purified as described above, they were all
autophosphorylated to slightly different basal levels (data not shown). From the
time-course autophosphorylation detection, we can conclude that R385 mutants are
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able to autophosphorylate as wild type within 30min.
We

then

determined if the

R385 mutants

were

still

activated by

autophosphorylation. To compare kinase activity of WtSrc and R385 mutants with or
without autophosphorylation, enzymes were pre-incubated in kinase assay buffer in
the presence or absence of Mg2+ for 30min. Based on the observation that the
autophosphorylation of WtSrc and R385 reached a plateau within 30min, we chose a
30-min pre-incubation to allow full phosphorylation on Tyr416. The relative kinase
activities with or without autophosphorylation were determined for WtSrc and R385
mutants (Figure 3.2). Src Y416F and Src Y527F mutants were included in the assay,
serving as controls that cannot be phosphorylated on either Tyr416 or Tyr527. When
Tyr416 was replaced by phenylalanine, there was no difference in kinase activity
with the presence or absence of Mg2+ in the pre-incubation because the lack of the
autophosphorylation site. WtSrc had ~2.3 fold of original activity with
autophosphorylation, and all R385 mutants and Src Y527F had similar patterns of
activation.
These results demonstrate that R385 is not necessary for Src activation
associated with autophosphorylation on Tyr416. This observation contradicts the
proposed function of R385 stabilizing the super active conformation of the kinase
domain when Tyr416 is phosphorylated. To this point, R385 is found not necessary
for either catalysis or activation through autophosphorylation, which is surprising.
This discovery led us to explore the role of R385 in other aspects of Src regulation.
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Figure 3.1
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Figure 3.1 Time course of the autophosphorylation of Src and R385 mutants
WtSrc and selected R385 mutants at 450nM kinase concentration were incubated in
kinase assay buffer. Aliquots were taken at indicated period of time and the
autophosphorylation was detected by a monoclonal antibody specific for
phosphorylated Tyr416.
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Figure 3.2
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Figure 3.2 Effect of R385 mutation on Src activation regulation associated with
autophosphorylation

WtSrc and R385 mutants at 450nM concentration were pre-incubated in the
presence or absence of Mg2+ in the kinase assay buffer for 30min and the kinase
activity of the wild type and the mutants at 3nM kinase concentration (diluted from
pre-incubation) was determined using polyE4Y as a substrate by the standard kinase
assay: white for the relative activity of unautophosphorylated enzyme (with the
absence of Mg2+ in the pre-incubation) and black for the relative activity of
autophosphorylated enzyme (with the presence of Mg2+ in the pre-incubation). The
Mg2+ concentration was compensated for in the final kinase assay.
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3.3.3 Effect of R385 mutation on dephosphorylation of phosphorylated Tyr416
by PTP1B
Phosphoprotein phosphatase reverses the action of protein kinases by catalyzing
the removal of the phosphate.

PTP1B is universally expressed and has the

potential of playing a role in Src regulation by catalyzing the dephosphorylation of
Src[8, 30]. A protection mechanism has been observed in the dephosphorylation of
the Tyr172 in the AMP-activated protein kinase (AMPK), which belongs to the family
of serine/threonine protein kinases[65]. Activation of AMPK requires the
phosphorylation of Tyr172 in the activation loop of the kinase domain and the bound
AMP not only stimulates AMPK but also protects the Tyr172 from dephosphorylation.
Based on the observation of the direct contact of the R385 with phosphorylated
tyrosine on the activation loop in the structure, it is plausible that R385 protects the
phosphorylated tyrosine from dephosphorylation by a phosphatase, which is a
similar mechanism as AMPK has.
Dephosphorylation of the phosphorylated Tyr416 on Src was examined for WtSrc
and R385 mutants. WtSrc, R385K and R385C mutants at 450nM kinase concentration
were first pre-incubated for 1 hour to achieve full autophosphorylation. Then the
autophosphorylated WtSrc and R385 mutants were treated with same amount of
PTP1B in the presence of Na2EDTA and fractions were removed at indicated period of
time for western blot analysis of the remaining phosphorylation level of Tyr416
(Figure 3.3). The presence of Na2EDTA should block autophosphorylation by
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chelating Mg2+. The amount of PTP1B added in the dephosphorylation assay was
optimized so that, the phosphorylation level of Tyr416 for WtSrc decreased gradually
in the time period tested. To ensure accurate determination of the rate difference in
dephosphorylation between WtSrc and R385 mutants, each mutant was tested side
by side with WtSrc and each experiment was repeated. To ensure the intensity of the
signal stayed in a linear range, the western blot results were processed using Image
LabTM Software and none of the signal used for calculation was saturated for
exposure. As shown in Figure 3.3(A), Tyr416 phosphorylation level of WtSrc and
R385K before PTP1B added was indicated as 0min time point in the
dephosphorylation assay. For each indicated time point after PTP1B was added, the
remaining Tyr416 phosphorylation level was determined and the relative remaining
phosphorylation compared with before PTP1B added was visualized on histogram.
The dephosphorylation of R385K was obviously faster than WtSrc. In the side-by-side
experiment between R385C and WtSrc, R385C also had a higher dephosphorylation
rate than WtSrc (Figure 3.3(B)). This result suggests that the interaction between
R385 and phosphorylated Y416 protects Tyr416 from dephosphorylation, a similar
regulatory mechanism as observed in AMPK.
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Figure 3.3 Effect of R385 mutation on the dephosphorylation of the
phosphorylated Tyr416 by PTP1B
WtSrc and R385 mutants at 450nM kinase concentration were incubated in the
kinase assay buffer for 60min allowing autophosphorylation. Then the same amount
of PTP1B and Na2EDTA were added and aliquots were taken at indicated period of
time. The remaining phosphorylation level was detected by a monoclonal antibody
specific for phosphorylated Tyr416. Each R385 mutant was tested side by side with
WtSrc and the phosphorylation intensity was visualized in histogram: (A)
dephosphorylation examination of WtSrc and R385K; (B) dephosphorylation
examination of WtSrc and R385C.
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3.3.4 Effect of R385 mutation on Src regulation by Csk phosphorylation of the
tail Tyr527
Csk phosphorylating Tyr527 on the C terminal tail of Src is another major
mechanism of Src regulation. To test the effect of R385 mutation on Csk inactivation
of Src, WtSrc and R385 mutants at 450nM were first pre-incubated with Csk at a
molar ratio of 1:1 for 30 min, and then enzymes from the pre-incubation were diluted
to 30nM or appropriate concentration for the standard kinase assay using Src optimal
peptide as a substrate (Figure 3.4). Csk dosen’t recognize Src optimal peptide as a
substrate. The original activity of unphosphorylated Src and mutants was determined
by pre-incubation in kinase assay buffer without Mg2+and the absence of Mg2+
prevented autophosphorylation in the pre-incubation. Src Y416F and Src Y527F were
included in the assays as controls. As seen in Figure 3.4, without tail tyrosine
phosphorylation by Csk, Src Y527F kinase activity wasn’t inhibited under this
described condition. Indeed, the activity of Y527F increased by 250% of the original
activity, which resulted from autophosphorylation in the pre-incubation. Activity of
all R385 mutants and Src Y416F decreased to ~30% of the original activity when
pre-incubated with Csk. This was in direct contrast with the WtSrc, which was not
inactivated by the incubation with Csk. This result isn’t consistent with what is
known about WtSrc. Csk inactivation of Src has been reported widely both in vivo and
in vitro [66, 67].
It has been demonstrated the Src inactivation requires stoichiometric amounts of
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Csk[24, 68]. To rule out the possibility that Csk used was not as active as expected,
higher Csk : Src molar ratios of 5 : 1, 10:1 or even 50: 1 were used in pre-incubation.
But still no inactivation by Csk for wt-Src was observed under these conditions (data
not shown).
It has been reported that autophosphorylation of Src and Yes, another Src family
member, blocks their inactivation by Csk[30]. We wondered if wild type Src
underwent autophosphorylation in the pre-incubation, which prevented its
inactivation by Csk. The fact Y416 was inactivated by Csk supports this possibility. To
test this possibility, autophosphorylation and tail phosphorylation were assessed
when Src was incubated in the kinase assay buffer with the presence of Csk. Src
incubated in the absence of Mg2+ or Csk served as controls. As seen in Figure 3.5,
WtSrc was purified with a basal level of autophosphorylation on Tyr416 and didn’t
autophosphorylate further more in the pre-incubation with the absence of Mg2+.
Significant autophosphorylation on Tyr416 was detected for WtSrc after
pre-incubation in kinase assay buffer regardless the presence or absence of Csk
(Figure 3.5B and 3.5C).

When Src was incubated in the presence of Csk, Tyr527 was

significantly phosphorylated as seen in figure 3.5D. R385 mutants had the same
patterns in the pre-incubation as wild type Src (data not shown). This demonstrated
autophosphorylation and phosphorylation on the tail by Csk both occurred in the
pre-incubation.
The double phosphorylated form of Src has been examined and activation of Src
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depends on phosphorylation on Tyr416 regardless of the phosphorylation status of
Tyr527[30]. Thus, autophosphorylation is likely the reason why WtSrc was not
inactivated by Csk under the described condition above. Autophosphorylation of Src
is by an intermolecular mechanism and thus concentration dependent[69]. To
minimize autophosphorylation during pre-incubation with Csk, WtSrc at 10nM
kinase concentration was pre-incubated with Csk at 5:1 or 10:1 Csk:Src molar ratio
for 30min and the phosphorylation status of Tyr416 and Tyr527 was examined at the
end of the pre-incubation. Under this condition described, the phosphorylation level
of Tyr527 was dominant, while autophosphorylation was minimized (Figure 3.6A).
The activity of Src was inactivated to ~50% of the original activity when
pre-incubated with Csk (Figure 3.6B). These observations demonstrate Src gets
inactivated by Csk only when it isn’t autophosphorylated, which is consistent with the
previous research.
So far, our results show that autophosphorylated R385 mutants can be regulated
by Csk inactivation, while autophosphorylation prevents Csk inactivation of wild type
Src. This raises the question why autophosphorylation does not seem to prevent
inactivation by Csk for R385 mutants. We tested this possibility directly.
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Figure 3.4 Effect of R385 mutation on Src inactivation by Csk regulation
WtSrc, R385 mutants, Src Y416F and Src Y527F at 450nM kinase concentration were
incubated with Csk at 1:1 ratio in kinase assay buffer for 30min and the kinase
activity of the wild type and the mutants at 30nM kinase concentration (diluted from
pre-incubation) was determined using Src optimal peptide as a substrate by the
standard kinase assay. Original activity was determined by pre-incubation in kinase
assay without Mg2+. The Mg2+ concentration was compensated at the final kinase
assay. The relative activity after Csk inactivation was presented.
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Figure 3.5

100

Figure 3.5 Phosphorylation status of Src when it was incubated with Csk
(A) WtSrc at 450nM kinase concentration was incubated in kinase assay buffer with
the absence of Mg2+. (B) WtSrc at 450nM kinase concentration was incubated in
kinase assay buffer with the presence of Mg2. (C) WtSrc at 450nM kinase
concentration was incubated with Csk at 1:1 ratio in kinase assay buffer. Aliquots
were taken at indicated period of time and the autophosphorylation was detected by
phosphorylated Tyr416 antibody for (A), (B) and (C). (D) WtSrc at 450nM kinase
concentration was incubated with Csk at 1:1 ratio in kinase assay buffer and the tail
phosphorylation was detected by phosphorylated Tyr527 antibody.
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Figure 3.6(A)
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Figure 3.6(B)
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Figure 3.6 WtSrc was inactivated by Csk only when WtSrc was not
autophosphorylated
(A) Phosphorylation status of WtSrc on Tyr416 and Tyr527 when WtSrc at 10nM
kinase concentration was pre-incubated with Csk at 5:1 or 10:1 Csk:Src ratio in
kinase assay buffer for 30min. The phosphorylation level was determined by western
blot with specific antibody at the end of the pre-incubation. (B) WtSrc at 10nM were
pre-incubated with Csk at 5:1 or 10:1 Csk:Src molar ratio in kinase assay buffer for
30min and the kinase activity of WtSrc activity at 30nM kinase concentration (diluted
from pre-incubation) was determined using Src optimal peptide as a substrate by the
standard kinase assay. Original activity was determined by pre-incubation in kinase
assay buffer with the absence of Mg2+. The Mg2+ concentration was compensated at
the final kinase assay. The relative activity after Csk inactivation was presented
compared with original activity.
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3.3.5 Effect of R385 mutation on Csk inactivation when Src was first
autophosphorylated
R385 mutants can be inactivated by Csk when autophosphorylated based on the
previous observations (Figure 3.4). However, it was not clear in the above
experiments whether R385 mutants were first inactivated by Csk and then not
affected by autophosphorylation or they are first autophosphorylated and then still
able to be inactivated by Csk. To test this question, we had the enzymes
autophosphorylated to maximum first and then incubated with Csk to see if the
activity was inactivated. WtSrc and R385K were first incubated at 450nM in kinase
assay buffer for 30 min allowing autophosphorylation and then Csk was added into
the reaction at 1:1 ratio for another 30 min. After the first 30min pre-incubation,
autophosphorylation should be saturated for WtSrc and R385K mutant based on
previous observation. WtSrc got significant autophosphorylation on both Tyr416 and
Tyr527 after the treatment (data not shown) and WtSrc was activated to ~238% of
the original catalytic activity (Figure 3.7). This result demonstrates that double
phosphorylated form of WtSrc maintains the active conformation, which is consistent
with what is known. R385K mutant with the same treatment got phosphorylated
significantly on both Tyr416 and Tyr527 similarly as WtSrc (data not shown).
However, R385 mutant in the double phosphorylated form was inactivated to ~35%
of the original activity. This result demonstrates that R385K can be inactivated by Csk
even when it is first autophosphorylated. The R385 mutation makes the auto
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phosphorylated kinase still subject to inactivation by phosphorylation on C terminal
tail. This result indicates that phosphorylation on the activation loop prevents the
transition from super active conformation to inactive conformation for Src even when
the tail tyrosine is phosphorylated; whereas, R385 mutation makes Src transition
from super active conformation to inactive conformation directly when the tail was
phosphorylated. This result suggests that R385 plays a crucial role in controlling the
conformational transition underlying the Src regulation by Csk phosphorylation.
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Figure 3.7 Inactivation by Csk when Src was first autophosphorylated
WtSrc and R385K were first pre-incubated at 450nM in kinase assay buffer for 30min
allowing autophosphorylation and then incubated with Csk at 1:1 ratio for another
30min. The kinase activity of the WtSrc and R385K at 30nM kinase concentration
(diluted from pre-incubation) was determined using Src optimal peptide as a
substrate by the standard kinase assay. WtSrc and R385K were pre-incubated at
450nM in kinase assay buffer for 60min in the absence of Csk or Mg2+ and then kinase
activity was determined as original activity. The Mg2+ concentration was
compensated for in the final kinase assay. The relative activity of Csk inactivation
when first autophosphorylated is presented compared with original activity.
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3.3.6 Effect of R385 mutation on Src affinity towards Type II inhibitors
Most of the current kinase inhibitors are ATP competitive and form one to three
hydrogen bonds with the kinase that are normally formed by the adenine ring of
ATP[38]. Based on their interaction with target kinases, PTK inhibitors are generally
classified into three types. Type III inhibitors are allosteric and target outside the
active site of kinases, which will not be discussed in this study. Type I inhibitors
constitute a majority of the ATP competitive inhibitors and bind to the active
conformation of protein kinases, while type II inhibitors bind to the inactive
conformation. A variety of inactive conformations have been observed even for a
single kinase, thus type II inhibitors can potentially achieve more selectivity by
exploiting energetic differences among the conformations of different kinases[63].
Results in the previous sections suggested that R385 plays an important role on
conformational transition of Src underlying its inactivation by Csk. In that case, it
would be expected that R385 might contribute to the conformational transition of Src
to an inactive conformation important for the binding of type II PTK inhibitors.
Most of the characterized type II inhibitors do not inhibit Src or have a relatively
low potency. Notably, imatinib is known to be highly selective and inhibit Abl well by
targeting the inactive conformation [44, 70]. While sharing strikingly high homology
with Abl, Src is not inhibited by imatinib. Ponatinib, another type II inhibitor, has high
potency

toward

Abl

(IC50=0.37nM)

and

very

low

potency

towards

Src(IC50=5.4nM)[71-73]. Sorafenib[74] is a multikinase inhibitor and its potency
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towards Abl or Src is not clear yet. Thus, Imatinib, ponatinib, and sorafenib were
selected as representative type II inhibitors in this study. They are all FDA-approved
cancer therapeutics and bind to the inactive conformation of protein kinases, as
demonstrated by crystallized structures[38].
IC50 of each inhibitor towards WtSrc and R385K mutant was determined as
described in the methods section. WtSrc and R385K at the same concentration were
assayed in the presence of a series of concentrations of each inhibitor. IC50 towards
each inhibitor was compared between WtSrc and R385K: R385K bound to imatinib
with an IC50 ~25 fold lower than to WtSrc (Figure 3.8); R385K mutation lowered the
IC50 of ponatinib toward Src by ~9 fold (Figure 3.9); R385K lowered the IC50 of Src
for sorefenib by ~72 fold (Figure 3.10). These data indicated that R385 mutation
improves the affinity of Src towards the type II PTK inhibitors. These results
demonstrated that wild type Src was not able to readily transition into the inactive
conformation, thus preventing the binding of the these type II inhibitors. The
mutation of R385K removed the energy barrier and enabled the mutation to readily
transition to the inactive conformation, which favored the binding of the type II
inhibitors. This conclusion is consistent with the finding in the previous section that
mutation of R385 enables active Src to be inactivated by Csk.

110

Figure 3.8
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Figure 3.8 Imatinib inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and R385K was measured in the standard kinase assay with the
presence of 0.064, 0.32, 1.6, 8, and 40uM imatinib and graphed as a relative
percentage

of

the

uninhibited

activity

WtSrc=432.76uM; R385K=17.38uM.
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Figure 3.9 Ponatinib inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and R385K was measured in the standard kinase assay with the
presence of 1.646, 4.938, 14.8, 44.4, and 133.2nM ponatinib and graphed as a relative
percentage

of

the

uninhibited

activity

WtSrc=182.00nM; R385K=20.61nM.
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Figure 3.10 Sorafenib inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and Src R385K was measured in the standard kinase assay with
the presence of 0.064, 0.32, 1.6, 8, and 40uM sorafenib and graphed as a relative
percentage

of

the

uninhibited

activity

WtSrc=117.27uM; R385K=1.62uM
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3.3.7 Effect of R385 mutation on Src affinity towards type I inhibitors
With the observation of improved affinity towards type II inhibitors as a result of
Arg385Lys mutation, the affinity of R385K toward type I PTK inhibitors was explored.
Because the Type I inhibitors bind to the active conformation of kinases, the mutation
was not expected to affect the binding of these inhibitors.
Both dasatinib[75] and bosutinib[76] are dual Src / Abl inhibitors, which are
known to bind to active conformation of Src family kinase and belong to type I
inhibitor[77]. The IC50 of WtSrc and R385K mutant towards each inhibitor was
determined as described above. As shown, WtSrc (3.12nM) and R385K (2.16nM) had
just the same IC50 towards dasatinib (Figure 3. 11). Consistent with this pattern, the
difference between WtSrc (4.88nM) and R385K (2.70nM) towards bosutinib was
almost negligible (Figure 3.12).
To ensure not just R385K mutant behave this way, the drug sensitivity of
dasatinib towards WtSrc and representative R385 mutants including R385V, R385K,
R385A, R385C and R385N was probed at a set concentration of Dasatinib, 4nM. As
shown in Figure 3.13, the kinase activity of WtSrc and R385 mutants was all inhibited
to a similar level, ~ 10-30% of the original activity. This result showed that WtSrc and
all R385 mutants had similar drug sensitivity towards dasatinib. It demonstrates that
R385 mutation is able to maintain the active site of kinases, instead of destabilizing it.
This is consistent with the previous finding that R385 mutation doesn’t destabilize
the

active

conformation

and

the

super
117

active

conformation

caused

by

autophosphorylation. Finally, it can be reasoned that R385 mutation may not stabilize
either the inactive or active conformation, but makes the transition from active
conformation to inactivation conformation easier.
All together, study of the R385 mutation towards PTK inhibitors demonstrates
that R385 plays an important role in controlling the conformational plasticity that
provides the basis of Src inactivation and Type II inhibitor binding.
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Figure 3.11 Dasatinib inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and Src R385K was measured in the presence of 0.064, 0.32, 1.6,
8, and 40nM dasatinib and graphed as a relative percentage of the uninhibited
activity to determine dasatinib’s IC50: WtSrc=3.12nM; R385K=2.16nM.
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Figure 3.12 Bosutinib inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and Src R385K was measured in the presence of 0.64, 3.2, 16, 80,
and 400nM bosutinib and graphed as a percentage of the uninhibited activity to
determine bosutinib’s IC50: WtSrc=4.88nM; R385K=2.70nM.
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Figure 3.13
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Figure 3.13 Drug sensitivity of dasatinib for WtSrc and selected R385 mutants
Relative kinase activity of WtSrc and R385 mutants at 3nM was determined by the
standard kinase assay in the presence of 4nM dasatinib compared with original
activity in the absence of dasatinib.
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3.3.8 R385 mutants can be used to study the property of novel PTK inhibitors
With the understanding of the R385 mutation functioning in transition between
different conformational states, affinity differences between WtSrc and R385
mutation towards a given inhibitor could be used to study the binding property of the
inhibitor towards Src in turn.
A-770041 and WH-4-023 are novel Lck inhibitors, and both are potent and
selective. A-770041 was found to be 300 fold selective for Lck over Fyn, another Src
family kinase [78]. WH-4-023 displays selectivity over a range of closely related
kinases, exhibiting >300-fold selectivity against p38α and KDR [79]. However, so far
there is still little known about the mechanism of the selectivity. Thus, we decided to
test the sensitivity of A-770041 and WH-4-023 towards WtSrc and R385K,
respectively. As shown (Figure 3.14 and 3.15), WtSrc (14.57uM) and R385K (1.08uM)
had distinct IC50 towards A-770041 and WtSrc (93.68nM) and R385K (20.70nM) had
3-fold different IC50 towards WH-4-023. The affinity difference between WtSrc and
R385K toward these inhibitors indicates that these inhibitors may act as type II
inhibitors and that the selectivity of A-770041 and WH-4-023 over closely related
kinases may result from the energetic differences among kinases. This discovery
helps the understanding of the selectivity of the two potent inhibitors against other
closely related kinases.
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Figure 3.14
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Figure 3.14 A-770041 inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and Src R385K was measured in the presence of 0.064, 0.32, 1.6,
8, and 40uM A-770041 and graphed as a relative percentage of the uninhibited
activity to determine A-770041’s IC50: WtSrc=14.57uM; R385K=1.08uM.
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Figure 3.15
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Figure 3.15 WH-4-023 inhibition comparison between WtSrc and Src R385K
The activity of WtSrc and Src R385K was measured in the presence of 0.64, 3.2, 16, 80,
and 400nM WH-4-023 and graphed as a relative percentage of the uninhibited
activity to determine WH-4-023’s IC50: WtSrc=93.68nM; R385K=20.70nM.
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3.4 Discussion
Although different conformations of the active site have been well demonstrated
in numerous PTKs[80], what controls different conformational status has not been
demonstrated in any. This current study demonstrates that the arginine in the HRD
motif plays a crucial role in the control of conformational transition in the protein
tyrosine kinase, Src.

R385 doesn’t play a role in catalysis

It has been demonstrated in the previous chapter that a quite wide range of
structurally diverse amino acids can replace the HRD arginine of Src and maintain
approaching full catalytic activity, consistent with previous reports of R385 mutation.
Mutation of the arginine to alanine in yeast PKA reduces the kinase activity to 10.5%
of the wild type activity, but still maintains the viability of the yeast[54]. The embryo
extracts of the HRD arginine to cysteine mutant of Drosophila Src64 has 90% of wild
type kinase activity[52]. Regarding the biological function during the development of
Src64, this mutant has no effect on microfilament contraction, ring canal growth or
hatching, but has defects in egg production[52]. The arginine in the HRD motif is
conserved in most protein kinases but not all, and some authors even identify the
HRD motif as an “HXD motif”[46]. All together, it suggests that the arginine is not
essential for catalysis of Src.
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R385 is not required for Src autophosphorylation or activation by
autophosphorylation

All R385 mutants still get autophosphorylated on Tyr416 and activated through
autophosphorylation as wild type Src, which is in direct contrast to the previous
understanding of the role of R385. In the leading model of Src activation,
phosphorylation of Tyr416 triggers an electrostatic switch and shifts the
conformational equilibrium to the stabilized active conformation. Upon Tyr416
phosphorylation, the activation loop adopts an active configuration, which has been
well-defined in the active forms of Lck [33]and insulin receptor tyrosine kinase[35].
The phosphorylated activation loop forms two strands that pack against the N lobe of
the kinase, pinned in place by coordination of the phosphorylated Tyr416 with two
arginines, Arg385 in the catalytic loop and Arg409 in the activation loop. Thus, the
role of the R385 was suggested to stabilize the active configuration of the activation
loop when it is phosphorylated[29]. Indeed, R385 mutation to unrelated amino acids
in this study can maintain not only the active conformation of the catalytic site, but
also the active configuration of the activation loop when it is phosphorylated for Src
activation.

R385

protects

phosphorylated

Tyr416

dephosphorylation
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in

the

activation

loop

from

The HRD arginine protects the phosphorylated Tyr416 in the activation loop
from dephosphorylation by PTP1B as demonstrated in this study. It is consistent with
the directed contact between the arginine and the phosphorylated tyrosine displayed
in the crystallized structure. This suggests that the R385 plays a role in preventing
the inactivation of Src by phosphatase. In other words, R385 prevents the disruption
of the active configuration of the activation loop when it is phosphorylated and thus
prevents the conformational transition to the inactivation conformation. Notably,
even the closely related lysine can't replace the arginine to prevent the
dephosphorylation or maintain the interaction with the phosphorylated tyrosine. It
suggests some other kind of interaction between the phosphorylated tyrosine and the
arginine in the structural environment, instead of the proposed salt-bridge formed
between the negative charged tyrosine and the positive charged arginine in the
previous research[29]. A similar regulatory mechanism has been observed in AMPK
that the small amphipathic �G-helix of the kinase domain is involved in AMPK
inactivation by protein phosphatase[65].

R385 is required for autophosphorylation to override the Src inactivation by
Csk

Src activity can be inactivated by Csk through an intramolecular interaction, but
the autophosphorylation on Tyr416 overrides this inactivation[30]. Upon
autophosphorylation, the activation loop is rearranged into the active configuration,
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which prevents the inactivation of Src. Phosphorylated Tyr416 and the rearranged
activation loop together play a kinetic proofreading role. This kind of phenomenon
has been well recognized in protein phosphorylation reactions as a way of error
correction[31]. However, it was observed in this study that all of the R385 mutants
can be readily inactivated by Csk even when it is first autophosphorylated on Tyr416.
This suggests that R385 prevents the disruption of the active configuration of the
activation loop induced by Csk phosphorylation and thus prevents the
conformational transition to the inactivation conformation. Furthermore, this result
contradicts the current understanding of the R385 function on the inactive
conformation. In the crystal structure of the inactive conformation of the Src kinase
domain[29], R385 forms salt-bridge with the conserved Glu310 located in the helix
αC and thus stabilizes the inactive configuration of the helix αC. However, all tested
R385 mutants can be inactivated by Csk readily and maintain the inactive
conformation. Indeed, R385 acts as an energy barrier and is only responsible in
preventing the disruption of the active configuration of the activation loop when
phosphorylated based on the observation in this study.

R385 is a key residue in differentiating Src and Abl in type II inhibitor binding

Ever since the discover of imatinib, a highly successful cancer therapeutic
commercially known as Gleevec, the selectivity of it towards Abl over other highly
homologous PTKs like Src has been intensely investigated[49, 81-84], but ultimately
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without a decisive success. Recently, the different selectivity is proposed to be due to
the thermodynamic penalty caused during conformational transition[84-86]. This
current study of the R385 mutation towards both type I and II inhibitors reveals HRD
arginine as a structural basis for the thermodynamic penalty caused during
conformational transition from active to inactive conformation proposed in the
previous research. First, R385 mutants with structurally diverse substitutions have
almost identical affinity towards type I PTK inhibitors as wild type, which target the
active conformation of the active site. This suggests that R385 is not essential in
maintaining the active conformation targeted by type I inhibitors. Second, strikingly
increased affinity toward type II PTK inhibitors is observed for R385 mutations with
structurally diverse substitutions compared to the wild type Src. Type II inhibitors
target the inactivate conformation of the active site. Upon binding with type II
inhibitors, the activation loop undergoes conformational change that flips the
aspartate in the DFG motif away from the active site and the phenylalanine into the
ATP binding site, the so called DFG-out conformation[44]. Thus, it suggests that R385
mutation removes the energetic barrier caused by the transition to the inactive
conformation of Src induced by the type II inhibitors. Also, R385 mutations with
structurally diverse substitutions can maintain the inactive conformation, which
binds well with the type II inhibitors. It suggests that R385 is not responsible in
stabilizing the inactive conformation of the active site. All together, evidence support
that the HRD arginine acts as energetic barrier and prevents the conformational
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transition from active conformation to inactive conformation when Src binds to a
type II inhibitor. The role of R385 as energetic barrier in small molecular inhibitors
binding is consistent with the role of it in Src inactivation by Csk.

R385 represents a control of the conformational transition of catalytic domin
from active to inactive

This current study on R385 provides a structural basis for the control of the
conformational transition of Src. Several lines of evidence presented above support
this. Src R385 acts as an energetic barrier in the transition from active configuration
to the inactive configuration and makes it easier when induced. This similar
regulation mechanism also has been observed in Abl. The interaction of the type II
inhibitors with Abl depends on the configuration of the activation loop[81, 84, 87].
Abl with phosphorylated activation loop is less sensitive to the type II inhibitors. Abl
pays an additional energetic penalty in adopting the DFG-out inactive conformation.
These observations make this energetic regulation in conformational transition well
recognized and R385 presents as a control of it in Src.

The unique function of R385 can also be used to study the binding property of
small molecular inhibitors in return, which is an essential research area in drug
design and development. The binding affinity of two novel inhibitors, A-770041 and
WH-4-023, towards wild type Src and R385K mutation was determined in this study.
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This characterization reveals that the thermodynamic penalty caused by
conformational transition might also contribute to the selectivity of these two
inhibitors.

This study leads to the identification of the crucial role of R385 in transition
between different conformational states. One question remains to be answered. What
is the role of the HRD arginine in Abl and other protein kinases, that have an arginine
in the HXD motif. Since both Abl and Src are conserved in this HRD motif, the arginine
must have a different regulatory roles compared with Src due to the very different
affinity towards imatinib. This implies that the HRD arginine doesn’t function alone,
but under the overall structural environment. This leads to more questions as to
what are these residues and how do they function synergistically with the regulatory
HRD arginine for different kinases. The Src R385 mutation could serve as a model for
the further study.
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3.5 Materials and methods
3.5.1 Reagents and chemicals
Consumables and culture media, or media components, were purchased from
Fisher Scientific. Inhibitors used were purchased from Selleckchem. Specific
antibodies were purchased from Cell Signaling Technology. All the other chemicals
were purchased from Sigma.
3.5.2 Expression and purification of Src and mutants
Src and Src mutants were constructed in pRSETA expression plasmid. The Src
constructs were expressed in Escherichia coli BL21(DE3)RIL cells harboring the
pREP4groESL expressing the GroES/EL chaperone and the pCDF-1B expressing
protein tyrosine phosphatase PTP1B. The (His)6-tagged Src constructs were purified
using immobilized Ni -iminodiacetic acid-agarose as described previously[62].
Concentration and purity of each enzyme were determined by Bradford assay and
SDS-PAGE, respectively. Purified enzymes were stored in 50% glycerol at -200C.
3.5.3 Expression and purification of PTP-1B, CSK and Src optimal peptide
Constructs of Csk tyrosine kinase, PTP-1B phosphatase, and Src optimal peptide
were expressed in DH5α cells using pGEX-4T-1 plasmid. As described previously, the
glutathione-S-transferase

(GST)-fusion

proteins

were

purified

using

glutathione-agarose resin[88]. Concentration purify of each enzyme were determined
by Bradford assay and SDS-PAGE, respectively. Purified enzymes were stored in 40%
glycerol at -200C. Peptide substrate were stored in -800C directly without glycerol.
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3.5.4 Kinase assay
Kinase activity of Src and mutants was determined by using polyE4Y, or Src
optimal peptide, and ATP as the substrates. The phosphorylation reactions were
performed in 50ul volumes at 25oC in the protein kinase assay buffer: 50 mM
N-(2-hydroxyethyl)piperazine-N′-3-propanesulfonic acid (pH 8.0) containing 5%
glycerol, 0.005% Triton X-100, and 0.05% 2-mercaptoethanol. The standard assay
used 12mM MgCl2, 0.2mM ATP, and 1mg ml–1 polyE4Y, or 10µM Src optimal peptide.
After a 30-min reaction time, 5ul of the kinase reaction mixture was mixed with 5ul
ADP-GloTM reagent and incubated for 40 min to stop the kinase reaction and deplete
the unconsumed ATP. 10ul Kinase Detection reagent was added and incubated for
another 30 min to convert produced ADP to ATP and introduce luciferase and
luciferin to detect converted ATP. Then the luminescence produced was measured by
a plate-reading luminometer. Assays were performed in duplicate, and each assay
was repeated three times with reproducible results. For kinase assays designed to
determine inhibitor’s IC50, inhibitors used in this study were dissolved in 10% DMSO,
diluted in series, and included within the kinase reaction.

3.5.5 Autophosphorylation assay of Src and mutants
To determine the effect of autophosphorylation on Src or a mutant, it was
allowed to autophosphorylate at 450 nM in kinase assay buffer described for 30 min.
At the end of the autophosphorylation reaction, the enzyme was diluted to
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appropriate concentration (3nM for wild type Src and usually a few fold higher for
mutants depends on the activity of the specific mutant) for kinase assay. To
determine the level of autophosphorylation of WtSrc or a mutant, the
autophosphorylation was carried out as above for 5min, 10min, 20min, 30min and up
to 1 hour. At indicated time, aliquots were removed and prepared for SDS-PAGE. The
autophosphorylation on Tyr416 was identified with specific phosphorylated Tyr416
antibody.

3.5.6 Phosphatase assay with phosphorylated Src on Tyr416 or mutants by
PTP-1B
Src and mutants were first autophosphorylated as described above for 1 hour to
achieve

fully

autophosphorylation

on

Ty416.

The

dephosphorylation

of

autophosphorylated Src and mutants at 337.5nM was performed by incubation with
the same amount of PTP-1B in the presence of 10mM Na2EDTA for 8 min. At indicated
time, aliquots were removed and prepared for SDS-PAGE. The phosphorylation levels
of Src and mutants on Tyr416 were visualized by western blot with a monoclonal
antibody specific for phosphorylated Tyr416 and quantified by band intensity. To
ensure precisely quantification, signal was captured at linear range and
dephosphorylation of Src and each mutant were done synchronously.
3.5.7 Csk inactivation assay of Src and mutants
To determine the inactivation of Src and mutants by Csk, the kinase activity of Src
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and mutants was assayed using Src optimal peptide as substrate in the presence of
Csk. Since Src optimal peptide is a far superior substrate for Src than Csk, kinase
assay for Src and mutants can be precisely performed without removing Csk in the
reaction. Src and mutants were first incubated with Csk for 30min and the
phosphorylation level on Try527 was determined by western blot with specific
phosphorylated Tyr527 antibody. After 30 min incubation with Csk, the enzyme was
diluted to appropriate concentration (1nM for Src and usually a few fold higher for
mutants depends on the activity of mutant) for kinase assaay.

3.5.8 Csk inactivation assay of Src and mutants when autophosphorylated
To determine the effect of Tyr416 phosphorylation on Csk inactivation, wild type
Src and mutants were first autophosphorylated at 450nM for 30 min, and then
incubated with Csk for another 30 min. Then enzymes were diluted to appropriate
concentration for the kinase assay as described above.
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